IR.AEGLEABIO.COM
Aeglea Biotherapeutics - Investors - InvestorsInvestor info Aeglea BioTherapeutics: researching enzyme treatment and therapeutic human engineered enzymes to help treat cancer and rare genetic disease.
http://ir.aegleabio.com/
Investor info Aeglea BioTherapeutics: researching enzyme treatment and therapeutic human engineered enzymes to help treat cancer and rare genetic disease.
http://ir.aegleabio.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
1.1 seconds
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
18
SITE IP
184.25.56.203
LOAD TIME
1.125 sec
SCORE
6.2
Aeglea Biotherapeutics - Investors - Investors | ir.aegleabio.com Reviews
https://ir.aegleabio.com
Investor info Aeglea BioTherapeutics: researching enzyme treatment and therapeutic human engineered enzymes to help treat cancer and rare genetic disease.
AEMase Methionine Degradation | Aeglea Biotherapeutics
http://aegleabio.com/pipeline/aemase-methionine-degradation
Targeting methionine dependence for oncology. The finding of tumor methionine dependence led to efforts to attempt dietary manipulation as an anti-cancer therapy. These efforts provided evidence of limited activity, but did not reduce methionine levels sufficiently. Enzyme mediated methionine depletion in animals results in far lower serum levels than nutritional restriction can achieve, suggesting that our therapeutic approach with an engineered human methionine-degrading enzyme is likely to ach...
AERase Arginine Degradation Enzyme | Aeglea Biotherapeutics
http://aegleabio.com/pipeline/aerase-arginine-degradation
MODULATION OF ARGININE LEVELS. Aeglea BioTherapeutics’s lead product candidate, AEB1102, is derived from human Arginase I. Modifications, which include the substitution of cobalt for the manganese cofactor and PEGylation, impart on AEB1102 both increased catalytic activity and serum stability compared to native Arginase I, making it potentially suitable as a therapeutic for the degradation of arginine in the circulation. AEB1102 as a potential treatment for extremes of Arginine metabolism.
About Us | Aeglea Biotherapeutics
http://aegleabio.com/about
Aeglea BioTherapeutics was founded in December 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. The convergence of discovery and technology has created a significant opportunity for Aeglea to potentially impact both the treatment of inborn errors of metabolism and cancer.
Careers | Aeglea Biotherapeutics
http://aegleabio.com/careers
We are looking for exceptional individuals with a passion for leading-edge technologies to join our team! We are currently recruiting for the following positions:. Clinical Project Management Director (download full position description [PDF]). Program Director (download full position description [PDF]). Associate Director/Director, Patient Advocacy (download full position description [PDF]). Notice to Recruiters/Staffing Agencies:.
Product Pipeline | Aeglea Biotherapeutics
http://aegleabio.com/pipeline
The Aeglea BioTherapeutics product pipeline consists of a suite of degrading enzyme treatments focused on pinpointing specific deficiencies within metabolism. With our focus only within the items in the product pipeline, we’re able to incorporate 100 percent of our energy into making our enzymes as successful as possible. As of current, our product pipeline consists of the enzymes AEB1102, AEB3103, AEB2109, and AEB4104. All four focus on degrading specific elements within the human metabolism.
Team | Aeglea Biotherapeutics
http://aegleabio.com/about/team
David G Lowe, Ph.D., Co-Founder, President and Chief Executive Officer. Sandra Rojas-Caro, M.D., Chief Medical Officer. Charles N York, M.B.A., Chief Financial Officer. Henry L Hebel, M.B.A., Vice President of Product Development. Scott W Rowlinson, Ph.D., Vice President of Research. Joseph E Tyler, M.S., Vice President of Manufacturing.
Board Members | Aeglea Biotherapeutics
http://aegleabio.com/about/board
David G Lowe, Ph.D., Co-Founder, President and Chief Executive Officer. Russell J Cox, Executive Vice President and Chief Operating Officer, Jazz Pharmaceuticals. Professor George Georgiou, Ph.D., Co-Founder. Sandy Mahatme, Senior Vice President and Chief Financial Officer, Sarepta Therapeutics. Anthony Quinn, M.B Ch.B, Ph.D., FRCP. Armen Shanafelt, Ph.D., Lilly Ventures.
Mission | Aeglea Biotherapeutics
http://aegleabio.com/about/mission
DEDICATED TO DEVELOPING NOVEL TREATMENTS FOR INBORN ERRORS OF METABOLISM AND CANCER. We hope to achieve this through:. Effecting enzyme replacement therapy in patients with inborn errors of metabolism using engineered human amino acid degrading enzymes. Exploiting abnormal amino acid metabolism in cancer cells to selectively target tumors. Applying molecular biomarkers to the identification of cancer patients with tumors that have metabolic vulnerabilities in amino acid metabolism.
AECase Cysteine degradation Enzyme | Aeglea Biotherapeutics
http://aegleabio.com/pipeline/aecase-cysteine-degradation
Targeting cysteine/cystine and oxidative stress for oncology.
TOTAL LINKS TO THIS WEBSITE
18
Advanced Disposal Services - Investors - Overview
Please Read and Agree to the Following Before Proceeding. Disposal and Recycling Services. Disposal and Recycling Services. Life Cycle of Trash. Material Recovery Facility (MRF) Diagram. Recycling Facts and Trivia. Recycling at Home and Work. Recycling Tips and Trivia. Recycling at Home and Work. Our business is your business. We’re committed to providing timely, transparent information to our investors every step of the way. Our business is your business. 302,000 commercial and industrial customers.
Overview :: Advaxis, Inc. (ADXS)
Advaxis, Inc. (NASDAQ: ADXS). Either directly or through strategic collaborations with recognized cancer centers of excellence. Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial. Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer. Advaxis Analyst and Investor Day in New York City. Gregory T. Mayes. 305 College Rd East. Princeton, NJ 08540. T: 609-452-9813 ext 102. View Detailed Stock Info.
株式会社アドウェイズIR情報
Associated Estates Realty Corp - Investor Relations
Aug 6, 2015. AEC is dual listed and trades on NASDAQ. Quotes delayed at least 20 minutes. Information provided by eSignal. Wells Fargo Shareowner Services. 1110 Centre Pointe Curve Suite 101. Mendota Heights, MN 55120-4100. The above transfer agent contact information is intended for individual investors who are interested in enrolling in our Dividend Reinvestment Plan in order to buy, sell or transfer AEC stock.
Aegerion Pharmaceuticals, Inc. - Overview
4:00 PM ET on Aug 7, 2015. Delayed at least 20 minutes. Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Press Releases View all. Aug 5, 2015. Aegerion Pharmaceuticals Announces Second Quarter 2015 Financial Results. Jul 27, 2015. Aegerion Pharmaceuticals Announces Leadership Changes to Support the Next Stage of Growth. Jul 13, 2015. Aug 7, 2015 at 4:00 PM ET.
Aeglea Biotherapeutics - Investors - Investors
Patients and Caregivers Overview. As of 01/11/17 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. Aeglea BioTherapeutics to Present at BMO Capital Markets Prescription for Success Healthcare Conference. AUSTIN, Texas, Dec. 07, 2016 (GLOBE NEWSWIRE) - Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases and cancer,. There are currently no events scheduled.
Shareholders and Investors | Aeroflot
Traffic and Financial Highlights. General Meeting of Shareholders. Traffic and Financial Highlights. General Meeting of Shareholders. Board of Directors Committees. Internal Audit and Revision Committee. One airline in Russia. Developing a global hub at Sheremetyevo airport. Aeroflot the best airline. One of the youngest fleets. In the industry globally. Aeroflot Group Announces Operating Results for November 2016. Aeroflot Announces 9M 2016 IFRS Financial Results. Download Annual Report 2015.
Акционерам и инвесторам | Aeroflot
День инвестора и аналитика. День инвестора и аналитика. Внутренний аудит и Ревизионная комиссия. Развитие хаба в аэропорту. Группа Аэрофлот объявляет операционные результаты за ноябрь 2016 года. Аэрофлот объявляет финансовые результаты по МСФО за 9 мес. 2016 года. Группа Аэрофлот объявляет операционные результаты за октябрь 2016 года. Скачать Годовой отчет за 2015 год. PDF 17.12 MB. Встречи с инвесторами (США). Раскрытие результатов Группы Аэрофлот по МСФО за 12М 2016. 26 декабря 2016 г.
Aspen Aerogels, Inc. - Investors - Investors Home
Product and Safety Data Sheets. Aspen Aerogels is a leading energy technology company providing innovative thermal management solutions to the $2.8 billion energy insulation market. Aspen Aerogels is a leading energy technology company providing innovative thermal management solutions to the $2.8 billion energy insulation market. Aspen Aerogels is a leading energy technology company providing innovative thermal management solutions to the $2.8 billion energy insulation market. August 6, 2015.
Investor Relations | Aerohive Networks
Solutions by Network Location. Solutions by Use Case. Technology Behind The Solution. Become an Aerohive Partner. Tech Docs and Online Traning. End of Life Products. Solutions by Network Location. Solutions by Use Case. Technology Behind The Solution. Become an Aerohive Partner. Tech Docs and Online Training. End of Life Products. As of August 14, 2015 -. Minimum 20 minute delay. Oppenheimer 18th Annual Technology, Internet and Communications Conference. Wednesday, August 12, 2015. Aerohive Networks Sele...
Investor Relations - Aerojet Rocketdyne Holdings
Welcome to the Aerojet Rocketdyne Holdings Investor Relations web site. Here you will find corporate governance, general financial and contact information. 4:00 PM ET on Aug 14, 2015. Latest company news and archived press releases. Officers and business unit leads, board of directors and governance documents. Latest earnings release, latest 10-K, proxy statement and share related items. Latest stock information, historic lookup, investment calculator, dividend history and ownership profile.
